Purpose. The pharmacology, pharmacokinetics, clinical efficacy, and safety of febuxostat are reviewed. Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the ...

After decades of studies, researchers from the University of the Philippines Manila (UPM) have developed a natural treatment ...

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impair ...

Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a ...

An alternative XOI, Febuxostat, was launched in the US in 2009 with the hope of treating individuals with gout, however while ...

Crawling into bed to rest her painful left toe, Mel Gardener winced as she covered herself with a cotton sheet. Even the touch of this light fabric was excruciating.

It is estimated that up to 20% of US gout patients on standard-of-care allopurinol or febuxostat are physiologically refractory to these treatments. 2,3 About Shanton's Phase 2b Gout Study Shanton ...

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma ...

An alternative XOI, Febuxostat, was launched in the US in 2009 with the hope of treating individuals with gout, however while Febuxostat achieved peak sales greater than US$450 million after its ...

An alternative XOI, Febuxostat, was launched in the US in 2009 with the hope of treating individuals with gout, however while Febuxostat achieved peak sales greater than US$450 million after its ...